Low-density lipoprotein metabolism in mice with soft tissue tumours

Hynds, Sharyn A.; Welsh, John; Stewart, James; Jack, Andrew; Soukop, M.; McArdle, C. S.; Calman, Kenneth C.; Packard, Christopher J.; Shepherd, James

doi:10.1016/0005-2760(84)90189-9

Cited by 52 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Studies also found in some tumors, such as human myeloid leukemia, endometrial cancer, choriocarcinoma, liver cancer, colon cancer and breast cancer, levels of serum cholesterol were lower than normal people. [3][4][5][6][7] In our past studies, we also found the similar results in gastric cancer. 8,9 When the level of cholesterol was reduced, the growth of cancer cells may be inhibited.…”

Section: Discussionsupporting

confidence: 76%

Simvastatin Inhibited the Growth of Gastric Cancer Cells

Qian¹

2014

UHOD

View full text Add to dashboard Cite

Statins are cholesterol-lowering drugs with multiple activities including anti-cancer effects. The objectives of this study were to examine the effects of simvastatin on gastric cancer cells in vivo. The mice models for gastric cancer cells SGC7901 were divided into two groups, control and experimental group. Simvastatin was administered orally to the experimental group, while saline given to the control group. We measured the volume and weight of tumors, and calculated RTV (relative tumor volume), T/C (relative added value of tumor) and the inhibition rate. The data was compared using t test (p< 0.05 was considered as statistically siginificant). Then the expression levels of PCNA, VEGF and Survivin in gastric cancer tissues were examined immunohistochemically. Our results showed that the volumes of tumors of the mice in control and experimental group were 1.943±0.

show abstract

Section: Discussionsupporting

confidence: 76%

Simvastatin Inhibited the Growth of Gastric Cancer Cells

Qian¹

2014

UHOD

View full text Add to dashboard Cite

show abstract

“…Expression of LDL receptors in the liver can be decreased by a diet enriched in cholesterol and triglycerides rich in saturated fatty acids (Angelin et al 1983: Dietschy et al 1993: Packard et al 1983). The expression of LDL receptors in the spleen and adrenals can be significantly reduced by the administration of bile salts and corticosteroids respectively (Hynds et al, 1984: Isaacsohn et al 1986). …”

Section: Discussionmentioning

confidence: 99%

Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes

Versluis¹,

Rensen²,

Rump³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Many tumours express relatively high levels of low-density lipoprotein (LDL) receptors on their membranes. The LDL receptor is, therefore, an attractive target for the selective delivery of antineoplastic drugs to tumour cells. We reported previously on the synthesis of small apolipoprotein E (apoE)-containing liposomes that behave in vivo in a very similar way to native LDL. In this study, we (LAD). Tissue distribution studies showed that LAD-loaded apoE liposomes were taken up and processed by the major LDL receptor-expressing organs (i.e. adrenals, liver and spleen). Of all other tissues, the tumour showed the highest uptake. The distribution pattems of LAD-loaded apoE liposomes and native LDL in the tumour-bearing mice were very similar, which supports the role of the LDL receptor in the disposition of the prodrug-loaded particles. The disposition of LAD followed the pattem of the liposomal carrier. We conclude that apoE liposomes enable LDL receptor-mediated specific delivery of antineoplastic (pro)

show abstract

“…This problem might be circumvented since animal studies indicate that it is possible to down-regulate the LDL-uptake in these organs by pretreatment with bile acids and steroids without affecting the uptake by the tumour (Hynds et al, 1984).…”

Section: Discussionmentioning

confidence: 99%

“…The lipid core of LDL yields unesterified cholesterol, which is used for membrane synthesis or as a precursor in steroid hormone synthesis. The rationale for using LDL as a carrier for cytotoxic drugs is that certain human leukaemic cells and tumour tissues have higher LDL receptor activity than the corresponding normal cells or tissues (Gal et al, 1981;Ho et al, 1978;Hynds et al, 1984;Norata et al, 1984;Vitols et al, 1984a).…”

mentioning

confidence: 99%

Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex

Vitols

Söderberg-Reid²,

Masquelier³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Previous studies have shown that human leukaemic cells and certain tumour tissues have a higher receptor-mediated uptake of low density lipoprotein (LDL) than the corresponding normal cells or tissues. LDL has therefore been proposed as a carrier for anti-cancer agents. In the current study, a water-insoluble mitoclomine derivative (WB 4291) was incorporated into LDL. The WB 4291 -LDL complex contained about 1,500 drug molecules per LDL particle and showed receptor-mediated toxicity in vitro as judged from the difference in growth inhibitory effect on normal and mutant (LDL-receptor-negative) cultured Chinese hamster ovary cells. However, cellular drug uptake did not exclusively occur by the receptor pathway since mutant cells were also affected to some extent. The LDL part of the complex had the same plasma clearance and organ distribution as native LDL after i.v. injection in mice and rabbits.

show abstract

Low-density lipoprotein metabolism in mice with soft tissue tumours

Cited by 52 publications

References 16 publications

Simvastatin Inhibited the Growth of Gastric Cancer Cells

Simvastatin Inhibited the Growth of Gastric Cancer Cells

Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes

Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex

Contact Info

Product

Resources

About